Intelligent Bio Solutions Inc/$INBS
1D1W1MYTD1Y5YMAX
About Intelligent Bio Solutions Inc
Intelligent Bio Solutions Inc is a medical technology company focused on developing and delivering intelligent, rapid, non-invasive testing and screening solutions. Its current active product is the Intelligent Fingerprinting Platform, consisting of a proprietary portable platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader. Its flagship product, the Intelligent Fingerprinting Drug Screening System, is a two-part system of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse, including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The Company operates in APAC, the UK, the Americas, and the rest of the world, with maximum revenue from the United Kingdom.
- Ticker
- $INBS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 60
- Headquarters
- New York, United States
- Website
- ibs.inc
INBS Metrics
BasicAdvanced
$7.1M
-
-$8.44
4.21
-
Price and volume
Market cap
$7.1M
Beta
4.21
52-week high
$24.90
52-week low
$1.52
Average daily volume
103K
Financial strength
Current ratio
1.44
Quick ratio
1.146
Long term debt to equity
31.605
Total debt to equity
34.383
Interest coverage (TTM)
-1,146.57%
Profitability
EBITDA (TTM)
-11.146
Gross margin (TTM)
48.63%
Net profit margin (TTM)
-294.91%
Operating margin (TTM)
-292.03%
Revenue per employee (TTM)
$70,000
Management effectiveness
Return on assets (TTM)
-76.20%
Return on equity (TTM)
-307.69%
Valuation
Price to revenue (TTM)
0.825
Price to book
1.24
Price to tangible book (TTM)
2.53
Price to free cash flow (TTM)
-0.288
Free cash flow yield (TTM)
-346.79%
Free cash flow per share (TTM)
-8.184
Growth
Revenue change (TTM)
38.09%
Earnings per share change (TTM)
-57.88%
3-year revenue growth (CAGR)
49.68%
INBS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.